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Introduction: Moyamoya disease is characterized by progressive steno-occlusive changes of the distal internal carotid
and developed collateral vasculature, so called ‘moyamoya’ vessels at the base of the brain. Variant angina is a rare
occurrence in patients with moyamoya disease.
Case presentation: Here we report the case of a 41-year-old Korean woman who developed chest pain after indirect
revascularization surgery of moyamoya disease. A treadmill test and an exercise stress echocardiograph showed positive
results, but there was no significant major coronary arteries stenosis. Suspicious of vasospasm, we conducted an
ergonovine spasm stimulation test, which demonstrated tight stenosis of her proximal left anterior descending artery.
At the site of spasm, intravascular ultrasound virtual histology showed intraluminal fibrous plaque.
Conclusion: Physicians who follow up patients with moyamoya disease would need to be aware of the possibility of
cardiac ischemia as well as neurological manifestations.
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Moyamoya disease is an uncommon condition charac-
terized by spontaneous bilateral stenosis or occlusion of
the terminal portion of the internal carotid artery and
other proximal portions of cerebral arteries accompanied
by collateral branches which on angiography seem hazy
like a puff of cigarette smoke [1]. Although the etiology
of moyamoya disease is unknown, reduced vasoreactivity
of cerebral vessels has been reported in moyamoya dis-
ease [2]. Autopsies have revealed decreased vessel size
with fibrous thickening of the intima with minimum
lipid deposition, internal elastic lamina degeneration and
no substantial inflammatory cell infiltration is seen in
the vascular wall [3]. There have been several reports of
involvement of extracranial vessels, especially the renal ar-
teries, in moyamoya disease [4] but few studies have pro-
vided evidence as to whether these patients developed
ischemic heart disease [5,6]. Here we report the first case* Correspondence: learnbyliving9@gmail.com
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tion test associated with moyamoya disease.
Case presentation
A 41-year-old Korean woman was admitted to our hos-
pital with the complaint of recurrent chest pain in Feb-
ruary 2014. The pain felt like squeezing of her chest,
which radiated to her left arm, occurred usually in the
morning or when it was getting cold, was aggravated by
stress and relieved by sublingual nitroglycerin spray. She
was diagnosed with moyamoya disease 8 years ago in
2006 and received indirect revascularization, encephalo-
duro-arterio-synangiosis (Figure 1A and B), she has had
chest pain since then. One month later, she underwent a
cardiology work up including exercise stress echocardi-
ography and coronary angiography (CAG) at another
hospital. Exercise stress echocardiography showed left
anterior descending artery (LAD) territory ischemia but
the CAG showed no significant coronary artery stenosis.
She was diagnosed with syndrome X and then referred
to a psychiatrist at that time. She had never smoked cig-
arettes, she was not a social drinker and she denied ais is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Figure 1 Brain magnetic resonance imaging and angiography after indirect revascularization (arrows). A: Magnetic resonance angiography,
coronal view; B: axial view.
A B
Figure 2 Coronary artery image demonstrating a hypoplastic right coronary artery without significant luminal narrowing of major vessels. A:
Coronary computed tomography angiography; B: coronary angiography showed no coronary artery lesion.
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plained of intermittent chest pain and the intensity of it
increased before she visited our hospital.
The results of laboratory tests including creatine kin-
ase, creatine kinase-MB, and troponin T were within
normal levels and electrocardiography showed sinus
rhythm with no ST-segment abnormality. Echocardiog-
raphy showed normal LV function and no regional wall
motion abnormality. A treadmill test showed positive re-
sult of ST-segment depression and chest discomfort at
stage 4. Coronary computed tomography angiography
and CAG (Figure 2A and B), showed a hypoplastic right
coronary artery without significant coronary artery sten-
osis. We performed a coronary spasm provocation test,
suspicious of vasospastic angina. Ergonovine 0.2mg was
injected three times intravenously at 5-minute intervals.
We achieved cine angiogram at 90 seconds after each er-
gonovine injection. Coronary angiography demonstrated
proximal LAD focal 95% stenosis after two administra-
tions of intravenous ergonovine; the patient complained
of typical chest pain and there were ST-segment changesA
B
Figure 3 Coronary angiography. A: Coronary angiography demonstrated pro
twice intravenous ergonovine administration. B: The patient complained of ty
administration. C: After injection of intracoronary nitroglycerin, the stenosis wa
injection of nitroglycerin.(Figure 3A and B). After injection of intracoronary nitro-
glycerin, the stenosis was completely resolved and her T
wave was normalized (Figure 3C and D). An intravascu-
lar ultrasound virtual histology (IVUS-VH) image for the
site of the spasm showed fibrous plaque occupying 33%
of the coronary luminal area (Figure 4).
Finally the patient was diagnosed with variant angina
and we prescribed calcium channel blocker, nitrate and
moderate dose of statin. Her chest pain seemed to be
controlled with those medications; however, her chest
pain recurred several months later. We added nicorandil
and non-dihydropyridine calcium channel blocker; we
are monitoring her every month at our out-patient clinic
and up to now there have been no further events.
Discussion
The incidence of moyamoya disease is higher in East
Asia, such as Japan and Korea, than in Western coun-
tries. Moyamoya disease is generally manifested by ische-
mic or hemorrhagic stroke (that is, hemiplegia, headache,
numbness, and so on) and occasionally accompanied byC
D
ximal left anterior descending artery focal 95% stenosis (arrow in A) after
pical chest pain and there was ST-segment changes after ergonovine
s completely resolved (arrow in C). D: The T wave was normalized after
A B
Figure 4 Intravascular ultrasound virtual histology image for the site of coronary spasm. A: The coronary lumen has 33% plaque. B: The
component of plaque is mostly fibrous material.
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sue disease and extracranial arterial system) [7]. Although
an association of moyamoya and renovascular disease is
well described [4], reports of coronary artery disease in
moyamoya disease are rare. To the best of our knowledge
only four cases of moyamoya disease with suspicious vari-
ant angina have been reported, but no studies have pro-
vided evidence as to variant angina proven vasospasm
and shown virtual histology of coronary artery as in this
patient [6,8].
Spontaneous occlusion of cerebrovascular moyamoya
disease is characterized by occlusive or stenotic lesions
at or around the terminal portions of the internal carotid
arteries and abnormal vascular networks at the base of
the brain. The obstructive lesions are caused by fibrous
thickening of the intima with minimum lipid deposition,
the internal elastic lamina is well preserved, and no sub-
stantial inflammatory cell infiltration is seen in the vas-
cular wall.
Many reports showed that the pulmonary, renal and
pancreatic arteries in patients with moyamoya disease
may manifest histopathologic changes similar to the
stenotic changes of the intracranial internal carotid
arteries [9,10]. Even though a few cases of coronary ar-
tery stenosis in patients with moyamoya disease have
been reported, the histopathology of these coronary le-
sions is similar to the findings of the carotid arteries of pa-
tients with moyamoya. Pathology has shown soft intimalproliferation with minimum lipid deposition which signifi-
cantly differs from typical atherosclerotic plaques. Usual
coronary artery spasm very often occurs at the site of
atheromatous plaques, which suggests that atheromatous
plaques could magnify the lumen diameter reduction. In
this case we showed coronary artery spasm within the site
of fibrous plaque in a patient with moyamoya disease. An
IVUS-VH finding of CAD in moyamoya disease reported
by Lee et al. showed intracoronary fibrous plaque similar
to our case [11]. The cellular proliferation and vascular
dysregulation in moyamoya and vascular smooth muscle
cell hyperreactivity in variant angina were suggested to
have a common pathogenic link. This finding indicates
that moyamoya disease may actually be an intracranial
manifestation in a systemic arterial disorder.
Another possible link between these disorders is gen-
etic and ethnic factors. The pathogenesis of moyamoya
disease is still unclear. Many reports suggest that genetic
factors might also contribute to the development of the
disease; data from an epidemiological study showed a
high incidence among the Japanese and Asian popula-
tion, together with a familial occurrence in approxi-
mately 10 to 15% of cases, which strongly suggests a
genetic etiology. An analysis of an American survey of
298 patients with moyamoya disease found an annual
prevalence of 0.086 per 100,000 which was significantly
lower than the 0.35 reported in a nationwide Japanese sur-
vey [12,13]. Similarly, an analysis of the epidemiological
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of the population are Asian and Pacific Islanders (56%),
found incidence and prevalence of moyamoya disease to
be higher than in the rest of the USA because of the larger
percentage of people of Asian ethnic origins [14]. The role
of genetic factors in the pathogenesis of variant angina has
also been suggested by the observation of a different
prevalence of vasospastic angina in Japanese and White
people. In the USA, the frequency is about 4% of patients
who underwent coronary angiography with positive er-
gonovine test, whereas in Japan, positive study rates
are in the rage of 30% [15,16]. Japanese patients are
much more likely to develop coronary artery vaso-
spasm than Caucasian patients.
Both Moyamoya disease and variant angina are more
frequent in Asian populations, including Japanese, than
in Caucasian populations. Although a specific associa-
tive mechanism between both diseases is not clear, a ra-
cial or a genetic characteristic might be related to the
pathogenesis. Further epidemiologic and genetic data
are needed to elucidate the correlated mechanism of
these diseases.
From the clinical point of view, it is important to cure
the ischemic attack of patients who have both moya-
moya and variant angina. This case suggests that moya-
moya disease might be regarded as a systemic vascular
disorder, and evaluation of the extracerebral cardiovas-
cular system is also required in this disease.
Conclusions
The etiology of moyamoya disease is still unknown, but
the disease can be regarded as a systemic arterial disease.
Physicians who follow up patients with moyamoya dis-
ease need to be aware of the possibility of cardiac ische-
mia as well as neurological manifestations. We believe
that educating patients about cardiac symptoms is also
important so that these patients will seek medical atten-
tion if cardiac symptoms manifest.
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